Ozempic vs Wegovy: same molecule, different labels

Both contain semaglutide

Ozempic and Wegovy are brands containing semaglutide, a GLP-1 receptor agonist. They are not two different molecules. The useful comparison is the exact product’s labeled use, route and presentation—not a brand-name dose conversion.

Current US information is broader than older “both are weekly injections” summaries. Ozempic has oral tablets as well as an injection label, and Wegovy’s current prescribing information covers injection and tablets. An article that ignores those formulations can give an outdated picture of the daily routine.

Compare each labeled presentation

The pediatric and MASH uses in the injection label should not be transferred to Wegovy tablets. The MASH indication also has accelerated-approval conditions tied to confirmation of clinical benefit. “Same molecule” does not erase those distinctions.

Route changes the routine, not just the packaging

A daily tablet and weekly injection involve different administration steps. Oral semaglutide labels specify a morning empty-stomach routine, plain-water limits and a waiting interval before food, drink or other oral medicines. The exact Instructions for Use are the source for those steps.

Injectable presentations have their own device instructions and storage rules. A brand name alone does not identify whether a package is a multidose pen, a prefilled syringe or another labeled presentation. That also matters for travel planning and supplies.

The Ozempic/Rybelsus oral document explicitly says the formulations are not substitutable milligram for milligram. Numbers on different packages are not a do-it-yourself switching table. Bring the exact prescription name and presentation into a pharmacy or prescriber conversation.

Do not move a trial result to every brand and route

A study of a particular semaglutide regimen answers a question about that regimen and population. For example, SURMOUNT-5 studied injectable semaglutide regimens against tirzepatide in adults with obesity without diabetes. It was not a comparison of every oral and injectable product now listed under these brands.

Similarly, a cardiovascular or kidney indication belongs to the specific evidence and label wording. It cannot be copied onto every product containing the molecule. Reading the indication section alongside the formulation is a more reliable shortcut than assigning each brand one broad slogan.

Questions that make the distinction useful

• What exact condition or outcome is this prescription addressing?
• Which route and device are actually prescribed?
• Where are the current Medication Guide and administration instructions?
• What does the storage section say for this presentation before and after first use?

Both brands carry important safety information, including a thyroid C-cell-tumor boxed warning, contraindications and warnings about gastrointestinal and other adverse effects. These convenience and indication distinctions do not establish that the products are interchangeable or risk-free. Personal selection belongs with the clinician who knows the relevant medical history.

Outside the US, names, approvals and presentations can differ. This article is a dated US-label comparison, not a worldwide availability or insurance guide.

Read next

• Oral vs injectable routines
• The direct molecule trial
• Medicine naming guide